← Leaderboards
Gregory J Wilson
Vanderbilt University
$43,886
Attributed
$43,886
Total exposure
6
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$43,886 · 6
By mechanism
M01$43,886 · 6
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Russell F Devore$1,184
- Philip J Browning$1,389,049
- Gordon R. Bernard$207,867,283
- Jennifer A Pietenpol$43,416,854
- Marylyn D Ritchie$17,567,522
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationClinical ResearchHuman SubjectAids TherapyChild (0-11)Pediatric AidsCombination ChemotherapyClinical Trial Phase IAdolescence (12-20)Antiaids AgentLongitudinal Human StudySulfamethoxazoleTrimethoprimAtovaquoneAzithromycinNonsmall Cell Lung CancerP53 Gene /ProteinPassive ImmunizationAids Related Neoplasm /CancerBirthCellular ImmunityCytotoxic T LymphocyteDendritic CellsDrug Screening /Evaluation
Grant awards (22)
Pediatric Late Outcomes Protocol$42,022
M01 · FY2004 · RR
A PHASE II/III RANDOMIZED, OPEN-LABEL STUDY OF COMBINIATION ANTIRETROVIRAL RE...$1,272
M01 · FY2004 · RR
FOUR DRUG COMBINATION THERAPIES--PRIOR ANTIRETROVIRAL EXPERIENCE$0
M01 · FY2002 · RR
SERIOUS BACTERIAL INFECTION PREVENTION IN AIDS CHILDREN$0
M01 · FY2002 · RR
NEVIRAPINE VS NEVIRAPINE PLACEBO TO PREVENT MATERNAL FETAL TRANSMISSION OF HIV$0
M01 · FY2002 · RR
COMPARE 4 ANTIRETROVIRAL REGIMENS CONTAINING COMBINATIONS PROTEASE INHIBITORS$0
M01 · FY2002 · RR
COMPARE 4 ANTIRETROVIRAL REGIMENS CONTAINING COMBINATIONS PROTEASE INHIBITORS$0
M01 · FY2001 · RR
SERIOUS BACTERIAL INFECTION PREVENTION IN AIDS CHILDREN$0
M01 · FY2001 · RR
SERIOUS BACTERIAL INFECTION PREVENTION IN AIDS CHILDREN$0
M01 · FY2001 · RR
FOUR DRUG COMBINATION THERAPIES--PRIOR ANTIRETROVIRAL EXPERIENCE$0
M01 · FY2001 · RR
FOUR DRUG COMBINATION THERAPIES--PRIOR ANTIRETROVIRAL EXPERIENCE$0
M01 · FY2001 · RR
FOUR DRUG COMBINATION THERAPIES--PRIOR ANTIRETROVIRAL EXPERIENCE$0
M01 · FY2001 · RR
SERIOUS BACTERIAL INFECTION PREVENTION IN AIDS CHILDREN$0
M01 · FY2001 · RR
NEVIRAPINE VS NEVIRAPINE PLACEBO TO PREVENT MATERNAL FETAL TRANSMISSION OF HIV$0
M01 · FY2001 · RR
NEVIRAPINE VS NEVIRAPINE PLACEBO TO PREVENT MATERNAL FETAL TRANSMISSION OF HIV$0
M01 · FY2001 · RR
NEVIRAPINE VS NEVIRAPINE PLACEBO TO PREVENT MATERNAL FETAL TRANSMISSION OF HIV$0
M01 · FY2001 · RR
COMPARE 4 ANTIRETROVIRAL REGIMENS CONTAINING COMBINATIONS PROTEASE INHIBITORS$0
M01 · FY2001 · RR
COMPARE 4 ANTIRETROVIRAL REGIMENS CONTAINING COMBINATIONS PROTEASE INHIBITORS$0
M01 · FY2001 · RR
COMPARE 4 ANTIRETROVIRAL REGIMENS CONTAINING COMBINATIONS PROTEASE INHIBITORS$592
M01 · FY2000 · RR
NEVIRAPINE VS NEVIRAPINE PLACEBO TO PREVENT MATERNAL FETAL TRANSMISSION OF HIV$0
M01 · FY2000 · RR
FOUR DRUG COMBINATION THERAPIES--PRIOR ANTIRETROVIRAL EXPERIENCE$0
M01 · FY2000 · RR
SERIOUS BACTERIAL INFECTION PREVENTION IN AIDS CHILDREN$0
M01 · FY2000 · RR